Drug intelligence / Profile preview

GF-1003

Development stage: Preclinical
Lead developer: GenFlow Biosciences
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

GF-1003 is a drug candidate being developed by Genflow Biosciences and EXO Biologics. It is an mRNA-based gene therapy that utilizes a novel exosome delivery system to encapsulate and transport Genflow’s proprietary centenarian SIRT6 gene. The primary therapeutic focus for GF-1003 is Werner Syndrome, with additional potential applications being explored for liver fibrosis and non-alcoholic steatohepatitis (NASH). The development is supported by non-dilutive research grants from the Belgian government's Wallonia region, aiming to expand Genflow's pipeline into aging-related indications.

Targets

SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on GF-1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF-1003.

Explore the full profile